Aclarion, Inc. (ACON)
| Previous Close | 0.2621 |
| Open | 0.2750 |
| Bid | 0.2610 x 1000 |
| Ask | 0.2750 x 800 |
| Day's Range | 0.2750 - 0.2750 |
| 52 Week Range | 0.2510 - 2.3700 |
| Volume | |
| Avg. Volume | 181,312 |
| Market Cap | 2.418M |
| Beta (5Y Monthly) | N/A |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | -0.5800 |
| Earnings Date | N/A |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | N/A |
- GlobeNewswire
Aclarion Announces Key Commercial Milestone With Completion of 1,000 Nociscan Exams
Pace of Nociscan orders accelerated 2.5x for the last 250 scans compared to the first 250 scans Further acceleration of scan volumes expected as MRIs are activated for the recently completed panel of 10 Key Opinion Leader (KOL) surgeons All commercial Nociscans to date have been completed on Siemens MRI scanners with additional acceleration of volumes expected as Philips scanners are onboarded BROOMFIELD, CO, Nov. 27, 2023 (GLOBE NEWSWIRE) -- via NewMediaWire -- Aclarion, Inc., (“Aclarion” or th
- GlobeNewswire
Aclarion Announces Achievement of Goal to Enroll 10 Leading Spine Surgery Key Opinion Leaders (KOLs) to Support Nociscan Adoption
Recruitment of a panel of leading KOL surgeons who believe Nociscan can improve the diagnosis and treatment of discogenic low back pain is a critical step to establishing Nociscan as standard of care. Aclarion’s KOL panel represents spine surgeons at some of the largest and most influential academic centers and private practices in the country, including leaders of national societies that advocate for protocols to improve clinical treatments. The Company intends to activate MRIs for each KOL sur
- GlobeNewswire
Aclarion Expands Immediate Nociscan Access Into New York City With Tenth Key Opinion Leader Surgeon Advisor Addition Roger Hartl, MD
Dr. Hartl is the Hansen-MacDonald Professor of Neurological Surgery and Director of Spinal Surgery at the Weill Cornell Brain and Spine Center in New York, and the co-director of New York-Presbyterian Och Spine. Dr. Hartl becomes Aclarion’s 2nd KOL to get access to an MRI center authorized to perform Nociscans, adding NYC to Denver as the second active KOL site. Aclarion will report on Nociscan volumes to date before the end of the year and add this key metric to quarterly reporting beginning in
